CoChat

Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration

Open access

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Meta-analyses of antidepressant medications have reported only modest benefits over placebo treatment, and when unpublished trial data are included, the benefit falls below accepted criteria for clinical significance. Yet, the efficacy of the antidepressants may also depend on the severity of initial depression scores. The purpose of this analysis is to establish the relation of baseline severity and antidepressant efficacy using a relevant dataset of published and unpublished clinical trials. METHODS AND FINDINGS: We obtained data on all clinical trials submitted to the US Food and Drug Administration (FDA) for the licensing of the four new-generation antidepressants for which full datasets were available. We then used meta-analytic techniques to assess linear and quadratic effects of initial severity on improvement scores for drug and placebo groups and on drug-placebo difference scores. Drug-placebo differences increased as a function of initial severity, rising from virtually no difference at moderate levels of initial depression to a relatively small difference for patients with very severe depression, reaching conventional criteria for clinical significance only for patients at the upper end of the very severely depressed category. Meta-regression analyses indicated that the relation of baseline severity and improvement was curvilinear in drug groups and showed a strong, negative linear component in placebo groups. CONCLUSIONS: Drug-placebo differences in antidepressant efficacy increase as a function of baseline severity, but are relatively small even for severely depressed patients. The relationship between initial severity and antidepressant efficacy is attributable to decreased responsiveness to placebo among very severely depressed patients, rather than to increased responsiveness to medication.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.0050045

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 QUOROM Flow Chart
Figure 1 QUOROM Flow ChartCC BY · PubMed Central
Figure 2 Mean Standardized Improvement as a Function of Initial Severity and Treatment Group Drug improvement is portrayed as red triangles around their solid red regression line and placebo improvement as blue circles around their dashed blue regression line; the green shaded area indicates the point at which comparisons of drug versus placebo reach the NICE clinical significance criterion of d = 0.50. Plotted values are sized according to their weight in analyses.
Figure 2 Mean Standardized Improvement as a Function of Initial Severity and Treatment Group Drug improvement is portrayed as red triangles around their solid red regression line and placebo improvement as blue circles around their dashed blue regression line; the green shaded area indicates the point at which comparisons of drug versus placebo reach the NICE clinical significance criterion of d = 0.50. Plotted values are sized according to their weight in analyses.CC BY · PubMed Central
Figure 3 Mean Standardized Improvement as a Function of Initial Severity and Treatment Group, Including Only Trials Whose Samples Had High Initial Severity Drug improvement is portrayed as red triangles around their solid red regression line and placebo improvement as blue circles around their dashed blue regression line; the green shaded area indicates the point at which comparisons of drug versus placebo reach the NICE clinical significance criterion of d = 0.50. Plotted values are sized according to their weight in analyses.
Figure 3 Mean Standardized Improvement as a Function of Initial Severity and Treatment Group, Including Only Trials Whose Samples Had High Initial Severity Drug improvement is portrayed as red triangles around their solid red regression line and placebo improvement as blue circles around their dashed blue regression line; the green shaded area indicates the point at which comparisons of drug versus placebo reach the NICE clinical significance criterion of d = 0.50. Plotted values are sized according to their weight in analyses.CC BY · PubMed Central
Figure 4 Mean Drug–Placebo Difference Scores as a Function of Initial Severity Plotted values are sized according to their sample sizes (n); the green line represents the NICE clinical significance criterion. The solid blue regression line represents the trend across all 35 trials; the dashed red line represents the trend excluding the left-most observation.
Figure 4 Mean Drug–Placebo Difference Scores as a Function of Initial Severity Plotted values are sized according to their sample sizes (n); the green line represents the NICE clinical significance criterion. The solid blue regression line represents the trend across all 35 trials; the dashed red line represents the trend excluding the left-most observation.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Research works printed but not linked: 3

  1. Lipsey MW Wilson DB 2001 Practical meta-analysis. Applied social research methods Volume 49. Thousand Oaks (California) Sage Publications 247
  2. Evans FJ 1974 The placebo response in pain reduction Adv Neurol 4 289 296
  3. Fabre LF Crimson L 1985 Efficacy of fluoxetine in outpatients with major depression Curr Ther Res Clin Exp 37 115 123

Cited by

See all 2,442

Metadata

Authors
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T.
Affiliations
  • University of Hull (GB)
  • University of Wyoming (US)
  • University of Connecticut (US)
  • University of Windsor (CA)
  • Institute for Safe Medication Practices (US)
Corresponding author
Kirsch, Irving
Venue
PLoS Medicine
Published
2008-02-26
Volume
5
Issue
2
Pages
e45
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W2153403353
Cited by
2,442
References
49
Citations by year
2026: 47 · 2025: 53 · 2024: 63 · 2023: 65 · 2022: 90 · 2021: 81 · 2020: 132 · 2019: 100 · 2018: 159 · 2017: 154 · 2016: 142 · 2015: 130 · 2014: 156 · 2013: 191 · 2012: 179
FWCI
24.87
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • PLoS Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (publishedVersion)
  • Research Online (University of Wollongong) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Keywords
antidepressants, antidepressant efficacy, placebo response, severe depression, clinical significance
MeSH terms
Antidepressive Agents, Clinical Trials as Topic, Depressive Disorder, Humans, Severity of Illness Index, United States, United States Food and Drug Administration, Databases, Factual

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration. https://app.cochat.ai/papers/10.1371/journal.pmed.0050045
The paper
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008). Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration. PLoS Medicine. https://doi.org/10.1371/journal.pmed.0050045

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.